Status:
COMPLETED
Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV
Lead Sponsor:
KU Leuven
Collaborating Sponsors:
Mildmay Uganda Limited
Conditions:
Cardiometabolic Syndrome
Dyslipidemias
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective loc...
Detailed Description
Suboptimal cardiometabolic health is on a disproportional rise in Low- and Middle-Income Countries (LMICs). In sub-Saharan Africa (SSA), cardiometabolic dysfunction is being exacerbated by the ongoing...
Eligibility Criteria
Inclusion
- Triglycerides ≥150 mg/dL
- TLD regimen (ART) for ≥12 months
- 95% ART adherence in last 6 months
- Virally suppressed (most recent results viral load suppressed within the last 12 months)
- PLWH aged ≥30≤60 years.
- No plans to change location in the next 6 months
Exclusion
- Taking dietary supplements
- TB co-infection, renal failure disease, liver cirrhosis, chronic pancreatitis
- Pregnancy and Lactation or regular sport activity
- Parallel participation in another clinical trial
- On treatment for; dyslipidemia, hypertension or diabetes and oral hypoglycemic drugs
- Very low blood pressure (\< 90/50 mmHg)
- Not willing to consent or unable to consent
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06058845
Start Date
October 1 2023
End Date
January 30 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kajjansi HCIV
Wakiso, Uganda, 256